The Lancet Oncology
Fecha de publicación: 4 September 2019
Autores: Mario Giuliano, MD., Francesco Schettini, MD.,
Carla Rognoni, PhD., Manuela Milani, MD., Prof Guy Jerusalem, MD., Thomas Bachelot, MD., et al.
Background: Although international guidelines support the administration of hormone therapies with or without targeted therapies in postmenopausal women with hormone-receptor-positive, HER2-negative metastatic breast cancer, upfront use of chemotherapy remains common even in the absence of visceral crisis. Because first-line or second-line treatments, or both, based on chemotherapy and on hormone therapy have been scarcely investigated in head-to-head randomised controlled trials, we aimed to compare these two different approaches.Leer más